REPL - レプリミュ―ン （Replimune Group Inc.）

Veleka PeeplesDyer , Director at Replimune Group (NASDAQ: REPL ), reported a large acquisition of company stock options on June 5, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that PeeplesDyer, Director at Replimune Group, a company in the Health Care sector, was just awarded stock options worth 50,400 shares of REPL. The options give PeeplesDyer the right to buy the company''s stock at $18.48 per share. Replimune Group shares are trading up 13.43% at $21.54 at the time of this writing on Monday morning. Since the current price is $21.54, this makes PeeplesDyer''s 50,400 shares worth … Full story available on Benzinga.com

https://www.investing.com/news/assorted/replimune-appoints-veleka-r-peeplesdyer-to-its-board-432SI-3098239

WOBURN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023 at 1:00 PM ET at the Marriot Marquis in New York NY.

WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 2-6, 2023.

Replimune Group (NASDAQ: REPL ) reported its Q4 earnings results on Thursday, May 18, 2023 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Replimune Group missed estimated earnings by 7.25%, reporting an EPS of $-0.74 … Full story available on Benzinga.com

Replimune (REPL) on Wednesday announced a proposed public offering of up to $125M of shares and pre-funded warrants. Read more on the offering here.

https://www.investing.com/news/pro/replimune-group-pt-raised-to-34-at-svb-leerink-432SI-2959482

Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX ) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC met the primary endpoint. TransCode Therapeutics, Inc. (NASDAQ: RNAZ ) shares climbed 59.1% to $0.6679 after the company reported withdrawal of registration statement. BioVie Inc. (NASDAQ: BIVI ) gained 26.2% to $5.87. BioVie recently announced results from two Phase 2 trials assessing NE3107''s potential in Parkinson''s Disease (PD) and Alzheimer''s Disease (AD). Bit Brother Limited (NASDAQ: BTB ) climbed 23.1% to $0.4680. Vor Biopharma Inc. (NASDAQ: VOR ) climbed 21.4% to $5.22 after the company disclosed initial clinical data from VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of tremtelectogene empogeditemcel or “trem-cel” (formerly VOR33) in patients with acute myeloid leukemia. Vor Bio also priced underwritten offering of 15.3 million shares of common stock at $4.30 per share.

Replimune Group Inc (NASDAQ: REPL ) announced initial data from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical evaluating RP1 (vusolimogene oderparepvec) combined with Bristol-Myers Squibb Co''s (NYSE: BMY ) Opdivo (nivolumab). The overall response rate (ORR) was 36%, and the complete response (CR) rate was 20% compared to the 12.5% shown in the prior 16 patients presented … Full story available on Benzinga.com

Replimune Group (REPL) announced a collaboration with Roche (RHHBY) (RHHBF) on Wednesday to study combination therapies for cancer. Read the full story here.

Credit Suisse AG cut its holdings in Replimune Group, Inc. (NASDAQ:REPL) by 26.4% during the second quarter, HoldingsChannel reports. The fund owned 14,250 shares of the companys stock after selling 5,104 shares during the period. Credit Suisse AGs holdings in Replimune Group were worth $547,000 at the end of the most recent quarter. A number []

Piper Sandler started coverage on shares of Replimune Group (NASDAQ:REPL) in a research note released on Friday morning, PriceTargets.com reports. The brokerage issued an overweight rating and a $52.00 price objective on the stock. REPL has been the subject of several other reports. HC Wainwright restated a buy rating and set a $59.00 target price []

Replimune Group, Inc. (NASDAQ:REPL) Director Fund Iv L.P. Omega sold 2,441 shares of the firms stock in a transaction that occurred on Thursday, November 18th. The stock was sold at an average price of $33.50, for a total transaction of $81,773.50. The sale was disclosed in a filing with the SEC, which is accessible through []

HC Wainwright reissued their buy rating on shares of Replimune Group (NASDAQ:REPL) in a research note issued to investors on Monday morning, Analyst Ratings Network reports. They currently have a $59.00 target price on the stock. REPL has been the subject of several other research reports. SVB Leerink lowered their price target on Replimune Group []

Replimune Group, Inc. (NASDAQ:REPL) Director Fund Iv L.P. Omega sold 3,817 shares of the companys stock in a transaction that occurred on Monday, November 8th. The shares were sold at an average price of $33.53, for a total value of $127,984.01. The sale was disclosed in a document filed with the SEC, which is accessible []